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As a secondary analysis of the VAST-D clinical trial data, we employed a multi-layered 
strategy to describe the complicated clinical features of Major Depressive Disorder (MDD) and 
the heterogeneity among depressive symptoms, using the following analytical approaches:  
(1) Cluster analysis was used to transform a large and heterogenous mix of survey questions into 
a small number of correlated MDD symptom clusters: Four robust and highly-interpretable MDD 
symptom clusters (core emotional, appetite and weight, sleep disorders, atypical) were identified 
within the VAST-D trial, consistent with the findings from other relevant studies.  
(2) Decision tree analysis was used to identify symptom thresholds with particularly effective 
discriminability in identifying remitters who were being treated with the three different study 
medications. Classification trees built for remission using a CART algorithm, were used for each 
of the three treatments and for the total cohort in the VAST-D study to facilitate: 
(a) Generation of practical guidance that could be used to inform decision-making in real clinical 
settings;  
(b) Identification of features for the sub-groups of patients showing low/high responses to each of 
the three treatments;  
(c) Identification of the most important factors for remission through the use of random forests.  
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A. Major Depressive Disorder 
Major depressive disorder (MDD, “depression”) espouses a spectrum of different 
symptoms spread across many axes of daily living, including mood, appetite, fatigue and 
socialization, each with their own range of severities.1,2  MDD affects approximately 16% of the 
U.S. population  at some point in their lives, however, only less than one-third of patients achieve 
remission with their first antidepressant.3,4 It is believed that a combination of biological, 
psychological, genetic and social factors are the major causes in the onset of a depressive condition. 
However, the exact cause and pathophysiology of MDD is not yet understood, and as a result 
prescription of treatment regimen remains empiric.  
Different rating scales have been developed to diagnose MDD and to measure symptom 
severity. All the commonly-used rating scales assess each of the nine DSM-IV-TR criterion 
symptom domains5 (Sleep disturbance, Sad mood, Appetite/weight, Concentration, Self-criticism, 
Suicidal ideation, Interest, Energy/fatigue, Psychomotor agitation/ retardation) with varying 
designs. While the extant rating scales have demonstrated great facility in diagnosing MDD, there 
is great interest in studying the structure and relative importance of each of these surveys, 




B. The VAST-D Clinical Trial for treatment of MDD 
Given the fact that only less than one-third of patients with MDD respond to their first 
antidepressant treatment and achieve remission, next-step treatments are in great demand for the 
large number of unresponsive patients. The VA Augmentation and Switching Treatments for 
Improving Depression Outcomes (VAST-D) – a multisite randomized, single-blind, parallel-group 
trial – was conducted to determine the relative effectiveness of three common alternate next-step 
treatments in patients whose MDD was unresponsive to prior antidepressant treatments. A total of 
1,522 veterans (mean age, 54.4 years; men, 1296 [85.2%]) were randomized to one of the three 
interventions – Switch to a different antidepressant, bupropion (n = 511); augment current 
treatment with bupropion (n = 506); or augment with an atypical antipsychotic, aripiprazole 
(n = 505). After a 12-week follow-up period, 28.9% participants in the augment-aripiprazole group, 
26.9% in the augment-bupropion group and 22.3% in the switch-to-bupropion group achieved 
remission respectively. The only significant, although modest, remission comparison was found 
between the augment-aripiprazole group and the switch-to-bupropion group. Full study design and 
results of the primary analysis are published elsewhere in detail.6,7 
 
C. Thesis Objectives 
Objective 1.a: To identify similar symptoms within Major Depressive Disorder by investigating 
its underlying grouping schemes, i.e. symptom clusters;   
Objective 1.b: To compare the grouping schemes of baseline MDD symptoms identified in our 
study and in other relevant studies: whether the groupings are robust across different studies using 
different diagnostic tools and study populations.   
Objective 2: To construct decision trees for remission for the three different study medications 
respectively. Based on the decision trees and relevant tree-based analyses, (a) to identify sub-
groups of patients showing low or high responsiveness within each study arm, and to pinpoint key 
features with thresholds distinguishing different sub-groups; (b) to identify the most important 
factors for remission by random forests. 
 
D. Overview of approach 
We first applied hierarchical clustering, an unsupervised machine learning method, to 
identify baseline symptom clusters. The symptom clusters captured the most important and concise 
information of depressive symptoms with reduced dimensions. That is, symptom cluster scores 
were further derived as informative and succinct summary of diverse MDD symptoms, by 
averaging the scores of multiple symptoms within the same cluster. After combining the newly-
derived symptom clusters information with other baseline data, we conducted decision tree 
analyses for each treatment group and for the study cohort as a whole: (a) The Classification and 
Regression Tree (CART) model was used to build single decision trees for remission for each 
treatment respectively. The graphical representation of possible remission status with certain 
conditions on patient features could be highly intuitive, especially in a clinical context.  
(b) Random forest, an ensemble machine learning method that aggregates the results of multiple 
single decision trees with less overfitting tendency yet less intuitive results, was then applied as a 
complement to single trees. The Importance of Variable indices evaluated by random forest were 
used to identify the most important factors for remission. Finally, we offered new insights into 
underlying structures of MDD symptoms and sub-groups of patients or specific symptoms that 
show high- or low-likelihood of treatment response to anti-depressants in general.  
a. Symptom Clustering  
Given the clinical diversity of MDD symptoms, it is essential, to investigate underlying 
coherent clusters of these diverse symptoms. The reduced symptom dimensions would not only 
provide insight into the underlying nature of the complex disorder, but also assist a great many 
relevant next-step studies and make the findings more interpretable. Some approximately 
consistent clusters of depression symptoms were identified in recent studies with different rating 
scales and different statistical approaches8-10. Using data collected in the VAST-D study, we 
replicated these symptom clusters and evaluated the robustness of the clusters identified across 
different studies. Our study will be the first to merge data from two different instruments together 
(PHQ-9 and QIDS-C16). By comparing the results from a merged dataset versus clusters obtained 
independently from a single instrument, we will provide valuable insight into the results obtained 
by others, specifically: do the different clusters obtained by various authors reflect their choices of 
diagnostic tool.   
Factor analysis and clustering are two major statistical methods for investigating 
underlying grouping schemes and relationships of various symptoms. Compared to factor analysis 
that produces complicated structural relationships between individual symptoms and higher-level 
groups (called factors in factor analysis), hierarchical clustering produces more concise results 
where each individual symptom is only assigned to one single cluster. We applied hierarchical 
clustering in the study for its simplicity of interpreting and visualizing results, given that our main 
purpose is to investigate the underlying grouping schemes of complicated depressive symptoms.  
To summarize, we first applied hierarchical clustering, an unsupervised machine learning 
method, to examine the baseline symptom clusters. Then we compared our symptom clusters to 
the ones identified in other studies. 
b. Decision Tree Analyses  
Due to the complexity of MDD and heterogeneity among depressive symptoms patients, 
some treatments tend to exhibit differential effectiveness with different patient groups. Many 
studies have been conducted to show promising evidence of subtypes of MDD based on biological 
variables or on clinical features11, indicating potential personalized diagnostics and medication 
strategies of MDD.12 However, research results diffuse slowly into clinical practice. In addition, 
remembering or even evaluating each treatment guideline on an individual symptom level is 
complicated and inefficient in clinical practice.  
Decision trees are a popular supervised machine learning technique, especially useful for 
classification problems. Tree-based learning algorithms are adept at producing high classification 
accuracy with very concise representation of gathered knowledge.13-15 The use of machine learning 
methods including decision tree techniques to assist in medical diagnosis, decision-making and 
prediction of medical and health conditions has received substantial attention from researchers in 
recent years.16-19 Further, being  non-parametric, tree based techniques afford  great flexibility (i.e. 
no constraints on the data type, no assumptions about the space distribution and the classifier 
structure) compared to other conventional modeling methods.   
With an interest in facilitating knowledge translation into clinical practice, our study 
implemented decision tree analyses to make highly intuitive and easy-to-implement guidelines for 
individualized treatment selections from the three alternative MDD anti-depressant treatment 
strategies in the VAST-D trial, and to identify sub-groups of patients or specific symptoms that 
show high- or low-likelihood of treatment response to each anti-depressant. To the best of our 
knowledge, ours is the first analytical approach that investigates MDD antidepressant therapy 
through the use of decision tree techniques. 
II. METHODS 
The study is a secondary analysis of the VAST-D randomized clinical trial. The primary 
objective of the VAST-D trial was to evaluate the effectiveness and safety of three treatment 
approaches for MDD.6,7 
A. VAST-D: Protocol summary and Study Population  
Participants were recruited from 35 VA medical centers. Patients were considered eligible 
for VAST-D if they had an MDD diagnosis, were non-responsive to at least one course of anti-
depressant treatment, and capable and willing to provide informed consent. The criterion for study 
entry was a score of 16 or more (indicating severe depression) on the Quick Inventory of 
Depressive Symptomatology-Clinician Rated (QIDS-C16) questionnaire after at least 6 weeks of 
treatment, or a score of 11 or more (indicating moderately severe depression) after at least 8 weeks 
of treatment with the three most recent weeks at a stable “optimal” dose.  
Patients were randomized to one of three treatments in a 1:1:1 ratio: switch to another 
antidepressant, namely bupropion sustained release (Sw; Randomized as Treatment A), 
augmentation of current treatment with bupropion sustained release (AB; Randomized as 
Treatment B), or augment current treatment with aripiprazole (AA; Randomized as Treatment C).  
A total of 1,522 study participants completed the study protocol and their remission status 
on or before Week 12 was determined. The primary outcome was remission (1=remission, 0= no 
remission), defined as a QIDS-C16 score of 5 or less at 2 consecutive scheduled follow-up visits 




B. Study Data 
In the study, we included all the 1522 participants who completed the study protocol of the 
VAST-D trial. The outcome measure in our study is the remission status (1=remission, 0=no 
remission), which is the primary outcome defined in the original VAST-D study. For the variables, 
we considered available baseline information included demographic information, smoking history 
and frequency, depression related information, vital signs of health, medication use, 
psychopathology assessments, adverse effect assessments, quality-of-life assessments, and the 
PHQ-9 patient Depression Questionnaire. A full description of all variables and instruments 
included in the study is shown in Appendix A.  
 
C. Statistical Analysis 
a. Symptom Clustering 
PHQ-9 and QIDS-C16 are the two instruments used in this part of analysis (See Appendix 
A for instrument descriptions). To measure the severity of MDD symptoms, there is a one-to-one 
correspondence between the nine items of the PHQ-9 questionnaire and the nine DSM-IV-TR 
domains of MDD symptoms. Further, there is a one/multiple-to-one correspondence between the 
sixteen items of the QIDS-C16 questionnaire and the nine domains. The rating scales are the same 
for all items within both questionnaires, ranging from 0 (least severity) to 3 (most severity). For 
the MDD symptom domains (Sleep, Appetite/Weight, Psychomotor) which are each measured by 
multiple items in the QIDS-C16 questionnaire, the domain score is the highest score among its 
related items. 
To obtain a more high-resolution dataset of the MDD symptoms, we focused on the 16 
MDD symptoms instead of the 9 symptom domains in the analysis. To obtain a more balanced 
view of the severity of each symptom, we averaged the corresponding clinician-rated and self-
rated symptom scores, of each patient. Based on the averaged scores, hierarchical clustering 
(Distance measure: Euclidean distance; Cluster agglomeration method: Ward’s method) was 
applied to identify the underlying clusters of symptoms.  
b. Decision Tree Analyses 
1. CART Modeling 
Using clinical and demographic data (see Appendix A), and the computed symptom cluster 
scores (average the symptom scores of each symptom cluster), classification and regression trees 
(CARTs) algorithms were applied to construct decision tree models. For each treatment group and 
for the total cohort, classification trees utilizing the CART algorithm were intended for the primary 
outcome (: 1 = remission, 0 = no remission).   
A decision tree is a hierarchically organized structure, with each node partitioning the 
predictor space into disjoint subspaces based on value of a predictor. And same decisions/ 
predictions are made for all data points on the same predictor subspace.  
The decision tree modeling mainly comprises two processes: splitting and pruning. The 
splitting process produces fully-grown trees utilizing the CART algorithm. The algorithm makes 
top-down recursive binary division of the predictor space into partitions. Each split is created after 
considering all the possible splits at each node by examining each predictor in turn. Then to choose 
the best split so that the resulting child nodes are the “purest”, measured by the reduction in an 
impurity index (Gini Index) with respect to the response. 
A pruning process follows the partitioning process to prevent potential overfitting issues 
by trimming the nodes of the tree in a bottom-up fashion: The fully-grown decision trees are further 
pruned back based on a cost-complexity algorithm, producing smaller trees with better cross-
validation properties.  
2. Random Forest 
Though highly interpretable, single trees are prone to over-fitting; thus, random forests 
were also evaluated to give more convincing results. Random forest is a versatile and powerful 
machine learning technique that mitigates possible overfitting problems of decision trees with 
robust results, by aggregating the results of a large number of uncorrelated decision trees (number 
of bootstrapped trees in the study: 500) into one final result. As the basic building block of a 
random forest, each classification tree is created by randomly selecting a pre-specified number of 
variables from all predictors in each splitting process without pruning (Number of variables at 
each split in the study: 9).  
Moreover, as a powerful dimensionality reduction method, random forest is adept at 
handling large data set with higher dimensionality and identifying the most significant predictors. 
It generates an index for each predictor variable representing the relative importance of that 
variable, in terms of Importance of Variable. Based on the importance index of each variable, we 
investigated most important factors (Top 10) for remission, respectively for each treatment group 
and for the total cohort. 
c. Software and packages 
We conducted all the analyses in R software. The “hclust” package was used for 
hierarchical clustering for symptom cluster analyses. The “rpart” package was used for building 
CART trees and the “randomForest” package was used for random forest analysis for the decision 
tree analyses.   
 
III. RESULTS AND DISCUSSION 
A. Symptom Clustering 
We found four highly-interpretable symptom clusters among the sixteen MDD symptoms 
that measure the nine symptom domains (Figure 1). The four symptom clusters comprise core 
emotional symptom cluster (bad mood, concentration/decision making, loss of 
interest/involvement, feelings of worthless/self-outlook, energy/fatigability), appetite and weight 
symptom cluster (weight/appetite increases/decreases), symptom cluster of sleep disorders (sleep-
onset Insomnia, early morning insomnia, mid-nocturnal insomnia, hypersomnia) and atypical 
symptom cluster (psychomotor agitation/slowing, suicidal ideation).  
More importantly, our finding shared a great consistency with the MDD symptom 
groupings found in other studies, adding value to the confidence of the theory of MDD symptom 
 
Figure 1 Dendrogram: Four MDD symptom clusters (baseline) identified by hierarchical clustering in the VAST-D study.  
clusters (Table 2). Romera8 performed factor analysis of the Zung self-rating depression scale 
(ZSDS) and found a clinical interpretable 4-factor structure – a core depressive factor, a cognitive 
factor, an anxiety factor and a somatic factor – respectively correspond to the core emotional, 
atypical, sleep and appetite/weight symptom clusters in our study. Li9 found three meaningful 
factors reflecting weight/appetite disturbance, general depressive symptoms and sleep disturbance 
– respectively correspond to the appetite/weight, core emotional, symptom clusters in our study – 
by means of exploratory and confirmatory factor analysis in a large sample of 6008 depressed Han 
Chinese women. Chekroud8 reported three robust symptom clusters - the sleep symptom cluster, 
core emotional symptom cluster and atypical cluster – validated with three data settings (QID-SR 
scale used in the STAR*D trial, QID-SR scale used in the CO-MED trial, HAM-D scale used in 
the STAR*D trial) by hierarchical clustering.   
Similar grouping schemes of diverse MDD symptoms were obtained by various studies 
using different instruments and were reproduced within VAST-D in our study. Therefore, these 
MDD symptom clusters are suggested to be robust given different choices of instruments or 
diagnostic tools. Besides uncovering the underlying nature of MDD symptoms, these meaningful 
symptom clusters could fuel relevant studies by condensing the information and/or reducing the 
dimension of diverse MDD symptoms. They could also assist clinicians with more concise 
knowledge of the list of MDD symptoms collected by different questionnaires in the clinical 




Table 1Summary of symptom clustering in three recent secondary analyses and our study 
Our study Romera, 20089 Li, 201310 Chekroud, 20178 
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▪ Suicidal rumination 
▪ Dissatisfaction 
General depressive  






▪ Loss of energy or 
fatigue 
▪ Feeling of 
worthlessness 
Core Emotional 




▪ Loss of interest 









▪ Loss of interest 
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▪ Reduced libido 
▪ Hypochondriasis 
Appetite and weight 
▪ Loss of appetite 
▪ Loss of weight 
▪ Increase of appetite 
▪ Increase of weight 
Somatic factor 
▪ Decreased appetite 
▪ Weight loss 
▪ Tachycardia 
Weight/appetite  
▪ Loss of appetite 
▪ Loss of weight 
▪ Increase of appetite 
▪ Increase of weight 
   
B. Decision Tree Analyses  
a. CART modeling 
Classification decision trees were built based on the CART algorithm, respectively for the 
three treatment groups and for the total cohort. In each situation, the predicted outcome (remission 
or not) for a certain patient could be quickly obtained by going through a decision path of some 
certain simple conditions. 
Figure 2 Classification trees for each of the three treatment groups in the VAST-D study (algorithm: CART). 
Within each node, the predicted outcome is in the first line: 0 – not remit, 1 – remit. The two decimals in the 
second line are the remission rate. Percentages in the third line is the proportion of participants in this node. 
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1. Personalized treatment selection from the three treatments in VAST-D 
 Here, we put forward an intuitive and easy to implement guideline for clinicians to make 
personalized treatment selection from the three MDD treatments in the VAST-D study, and the 
logic could be extended to other existing treatments if data available:  
(1) For a given patient, a clinician could quickly go through the decision tree and record the 
predicted result (remission or not and/or probability of remission) under each of the treatment 
scenarios. 
(2) Then summarize the predicted results over the three (or more) treatments and make the 
selection.  
For example, a patient is predicted to remit for treatment A while not to remit for treatment 
B or C. Obviously, treatment A would be the suggested individualized treatment for that patient. 
Likewise, a treatment would be suggested if its predicted probability of remission is obviously 
higher than the predicted remission probabilities of other treatments. 
Naturally, classifiers derived from group analyses yield probabilistic statements about a 
deterministic phenomenon: the patient will either remit or not, and the probability can only provide 
a statement about the likelihood of an individual outcome given a knowledge-based obtained from 
others. In these situations, the guideline is still valuable to simply and quickly exclude or screen 
out some treatments with based on the best available information. The final decision could then be 





2. Highly responsive/unresponsive sub-groups of MDD patients 
Sub-groups of patients or specific symptoms that show high- or low-likelihood of treatment 
response to anti-depressants were identified by evaluating the terminal nodes of each classification 
tree using the VAST-D data.  
For a decision tree, the feature space of all terminal nodes is mutually exclusive and 
collectively exhaustive, and each terminal node represents a group of patients with similar features 
indicated by its previous nodes. By evaluating the average remission rate and proportion of patients 
of that terminal node, we distinguished highly responsive/unresponsive sub-groups of MDD 
patients.  Comparisons were based on the results of the primary analysis in the VAST-D study:  
The remission rate of treatment A is 22.3%; The remission rate of treatment B is 26.9%; 
The remission rate of treatment C is 28.9%.  
 
Table 2 Features of highly unresponsive subgroups of MDD patients within each treatment group  
             (There is no highly unresponsive subgroup identified for treatment A)  
Highly unresponsive sub-groups of MDD patients for Treatment B 
(Overall remission rate of treatment B: 26.9%) 
Sub-group b1 
(Sub-group remission rate 17%; Proportion of the treatment group 61%) 
Conditions Interpretation 
QIDS Total Score < 16 
Higher levels of clinician-rated depressive  
symptoms in general 
Highly unresponsive sub-groups of MDD patients for Treatment C 
(Overall remission rate of treatment C: 28.9%) 
Sub-group c1 
(Sub-group remission 17%; Proportion of the treatment group 62%) 
Conditions Interpretation 




Table 3 Features of Highly responsive subgroups of MDD patients within each treatment group 
Highly responsive sub-groups of MDD patients for Treatment A 
(Overall remission rate of treatment A: 22.3%) 
Sub-group A1 
(Sub-group remission rate 85%; Proportion of the treatment group 4%) 
Conditions Interpretation 
 
PHQ-9 total Score < 7.5 
& 
Core Emotional Symptom Cluster Score < 1.4 
Lower levels of patient self-rated depressive symptoms 
in general 
& 
Lower levels of core emotional symptoms 
Highly responsive sub-groups of MDD patients for Treatment B 
(Overall remission rate of treatment B: 26.9%) 
Sub-group B1 
(Sub-group Remission rate 83%; Proportion of the treatment group 2%) 
Conditions Interpretation 
 
QIDS Total Score < 16 
& 
PHQ-9 Agitation Item Score >= 2.5 
Lower levels of clinician-rated depressive 
 symptoms in general  
& 
Higher levels of patient-rated psychomotor agitation 
Sub-group B2 
(Sub-group remission rate 62%; Proportion of the treatment group 11%) 
Conditions Interpretation 
 
QIDS Total Score < 16 
& 
PHQ-9 Agitation Item Score < 2.5 
& 
BAI Total Score < 12 
& 
Positive Mental Health Score > 16 
Lower levels of clinician-rated depressive 
symptoms in general 
& 
Lower levels of patient-rated psychomotor agitation 
& 
Lower levels of self-report anxiety in general 
& 
Higher levels of positive mental health 
Highly responsive sub-groups of MDD patients for Treatment C 
(Overall remission rate of treatment C: 28.9%) 
Sub-group C1 
(Sub-group remission rate 80%; Proportion of the treatment group 6%) 
Conditions Interpretation 
Core Emotional Symptom Cluster Score < 2 
& 
QIDS Mid-nocturnal Item Score < 0.5 
Lower levels of core emotional symptoms 
& 
Lower levels of mid-nocturnal symptoms 
Sub-group C2 
(Sub-group remission rate 61%; Proportion of the treatment group 11%) 
Conditions Interpretation 
Core Emotional Symptom Cluster Score < 2 
& 
BAI Total Score < 12 
& 
QIDS Mid-nocturnal Item Score >= 0.5 
Lower levels of core emotional symptoms 
& 
Lower levels of self-report anxiety in general 
& 
Higher levels of mid-nocturnal symptoms 
b. Random Forest: Important factors for Remission 
According to the Importance of Variable indices by random forests, we evaluated ten most 
important variables in predicting the binary outcome (remission), respectively for each treatment 
group and for the total cohort. BAI (Beck Anxiety Inventory) total score, duration of trial and BMI 
are the three most important factors for remission for treatment A; BAI total score, duration of 
trial and age are the three most important factors for remission for treatment B; QIDS total score, 
BAI total score and core emotional symptom cluster score are the three most important factors for 
remission for treatment C; BAI total score, QIDS total score, BMI are the three most important 
factors for remission in general.  
An interesting finding is the consistency of significant variables across situations: The four 
situations have exactly the same ten most important factors for remission with different rankings. 
The great consistency may implicate most important factors for MDD remission, and fuel related 
studies concerning a dimensional reduction or model selection process.  
In a clinical context, these top factors could assist clinicians to make rough but quick 






Figure 3 Random Forest Results – Ten most important factors for remission according to the Importance of Variable index  
Table 4 Detail information of the ten significant factors for remission.  
CoreEmotScore Score of the core emotional symptom cluster 
CIRSscore Total score of the Cumulative Illness Rating Scale 
phq9TotScore Total score of the Patient Health Questionnaire 
CIRSseverity_index Severity index of the Cumulative Illness Rating Scale 
PosHlthscore Score of the Positive Mental Health instrument 
AGE Age of the patient 
BMI Body Mass Index (WeightLb/(HeightIn*HeightIn))*703 
Dur_Trial_Months Duration of index treatment trial (months) 
qidsTotalscore Total score of the 16-item Quick Inventory of Depressive Symptomatology  
baiTotScore Total Score of the Beck Anxiety Inventory 
C. Limitations 
The biggest limitation of the study is the inability to generalize the findings: First, potential 
solutions included in the proposed guidelines for the individualized treatment selection of MDD 
are limited to the three treatments in the VAST-D trial. However, it is likely that more alternate 
treatments are considered in a real situation. On the other hand, the guidelines could be easily 
extended to more solutions by the same framework if data available. Second, decision trees are 
prone to overfitting. That is, the trees may have better performance in predicting the outcome for 
the VAST-D trial data than for new data. Although the pruned trees with smaller number of layers 
in our study could reduce the likelihood of the problem theoretically, the robustness of the tree-
based models is expected to be further tested and validated in other relevant studies. Third, older 
male VA patients predominated in the study participants (mean age, 54.4 years; men, 1296 
[85.2%]). Therefore, whether the results could be further generalized to a broader population is 
unknown. To adjust the results for a broader population, analysis on different study populations 
using same or similar procedures is suggested. Another concern is that the VAST-D studied 
patients who had already failed at least one medication, and therefore, the results from our study 
may not be appropriate for newly diagnosed MDD patients. We expect to apply same or similar 
procedures proposed in our study on MDD patients with their first treatments. And if our technique 
could be extended to studies of first-line medication for MDD treatments, it would be a great 
opportunity to decrease the first-time failure rates. 
Improvements could be made in the findings of most important factors for MDD remission 
identified in our study using random forests: Besides the relative importance of each factor, more 
informative results could be obtained if the magnitude and direction of influence on remission of 
each factor were complemented. Integrating the results of a logistic regression or cox regression 
model on the same VAST-D study data is suggested in the next step analysis to: 1) provide 
supplemental information (magnitudes and signs of coefficients) that how the  important variables 
identified by random forest influence the results (remission); 2) compare the significant variables 
from regression models (may after a model selection procedure) with the important variables from 
random forests and investigate the consistency and difference. And new insights are expected by 
comparing our results using random forests within VAST-D study to other studies with similar 
purposes based on different statistical methods and data setting.  
 
IV. CONCLUSION 
In the study, we first applied hierarchical clustering on the baseline data of the VAST-D 
trial and identified four highly-interpretable clusters for the sixteen MDD symptoms included in 
the PHQ-9 and QIDS-C16 questionnaires. The four symptom clusters (core emotional, appetite 
and weight, sleep disorders, atypical) share great consistency with the findings from other studies 
using other different MDD instruments and/or statistical methods. Therefore, our findings provide 
new evidence in support of the theory of symptom clusters of MDD by reproducing the grouping 
schemes of MDD symptoms in the PHQ-9 and QIDS-C16 instruments. 
In support of knowledge translation and clinical application via MDD personalized 
treatment selection, we are the first to implement decision tree analytical techniques in this field 
and to propose an easy-to-implement and dependable guideline in a clinical context. Compared to 
most regression models for similar study objectives that produce significance levels and 
coefficients for each covariates, decision tree models are easy to understand and interpret for 
people with or without statistical background, and their graphical display could be easily 
interpreted and adopted in the clinical setting. By quickly going through the three decision trees 
generated in the study based on the CART algorithm, an individualized treatment suggestion 
among the three alternative anti-depressants could be obtained for each MDD patient. Of course, 
the final treatment decision should consider other important factors including clinicians' 
experience and judgement and significant findings from other studies. Subgroups of patients with 
similar features that have specific high/low response to each treatment within the VAST-D trial 
were also evaluated from the decision trees. 
Finally, we screened out ten most important factors from a great many factors for MDD 
remission using random forests. Together with the findings of the four robust symptom clusters, 
valuable insights into the underlying structure of complicated MDD symptoms and other related 
features are proposed that could assist in clinical management of patients.  
 
V. Appendix A 
Following patient-level data were included in the analysis:  
▪ Patient study number, randomized group assignment and participating site number, 
duration of index treatment trial in months, outcomes (=1 remission, =0 not remission);  
▪ Demographics: age, sex, marital status, education level, employment, race, ethnics; health 
status (BMI, alcohol/drug use history and frequency, total score and severity index of the 
CIRS);  
▪ Psychopathology assessments include total scores of the QIDS-C16, PHQ-9, PMH and BAI 
instruments; indicators of recurrent mania or depressant, and PTSD; the CGI-Severity 
index;  
▪ MDD symptom scores and nine DSM-IV-TR criterion symptom domains scores:  
- For the PHQ-9 instrument, the nine symptom scores (score of each item) are the nine 
corresponding symptom domain scores.  
- For the QIDS-C16 instrument, there are 16 MDD symptom scores (scores of the 16 
items) and 9 symptom domain scores: If there is a one-to-one correspondence between 
the item and the MDD symptom domain, then the domain score is the item score, if 
there is a multiple-to-one correspondence between the items and the symptom domain, 
then the domain score is the highest score of the items of that domain) 
 
Table for Appendix A. Brief description of measures used in the study 






A 16-item clinician-rated depression scale that adopts a  
4-point scale: 0 – 3, higher scores indicate higher degree of 
severity of that depression symptom during the past 7 days.  
The 16 items have a one/multiple-to-one correspondence 
to the nine DSM-IV symptom criterion domains: Sleep 
disturbance domain - Initial, middle, and late insomnia or 
hypersomnia (Q1-Q4), Sad mood domain (Q5), Appetite/ 
weight domain - Decrease/increase in appetite/weight (Q6-
Q9), Concentration domain (Q10), Self-criticism domain 
(Q11), Suicidal ideation domain (Q12), Interest domain 
(Q13), Energy/fatigue domain (Q14), Psychomotor 
domain – Psychomotor agitation/retardation (Q15-16).  
The score of each domain is the highest score of the items 
within that domain. And the total score of the instrument is 
the sum of all the nine domain scores, indicating the 





A 9-item self-report depression scale that adopts a 4-point 
scale (0 – 3, higher scores indicate higher frequencies of 
being bothered by that item during the last 2 weeks), where 
each item corresponds to each of the nine DSM-IV-TR 
criterion symptom domains. The total score is the sum of 
the 9 items. Higher scores indicate higher degree of 





A 47-item instrument included six subscales: general 
coping (9 items), emotional support (7 items), spirituality 
(7 items), interpersonal skills (9 items), personal growth 
and autonomy (10 items), and global affect (5 items). 




A 21-item self-report anxiety scale adopts a 4-point scale 
(0 = not at all, 1 = mildly, 2 = moderately, 3 = severely). 
The total score is the sum of the 21 items (0-21 = low 
anxiety, 22-35 = moderate anxiety, 36 or above = 
potentially concerning levels of anxiety). Higher scores 





A one-item clinician-rated index that evaluates the severity 






One of the commonly used tools to measure comorbidity 
that measures the chronic medical illness burden with the 
severity of chronic diseases considered. Higher score 
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